HilleVax, Inc. – NASDAQ:HLVX
HilleVax stock price today
$2.06
+0.12
+6.19%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
HilleVax stock price monthly change
+10.86%
month
HilleVax stock price quarterly change
+10.86%
quarter
HilleVax stock price yearly change
-88.66%
year
HilleVax key metrics
Market Cap | 91.39M |
Enterprise value | 265.47M |
P/E | -3.09 |
EV/Sales | N/A |
EV/EBITDA | -1.69 |
Price/Sales | N/A |
Price/Book | 1.90 |
PEG ratio | 0.03 |
EPS | -3.3 |
Revenue | N/A |
EBITDA | -134.22M |
Income | -143.50M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHilleVax stock price history
HilleVax stock forecast
HilleVax financial statements
| Jun 2023 | 0 | -27.90M | |
|---|---|---|---|
| Sep 2023 | 0 | -31.81M | |
| Dec 2023 | 2.86M | -36.96M | -1290.5% |
| Mar 2024 | 0 | -46.82M |
| 2025 | 0 | -183.83M | |
|---|---|---|---|
| 2026 | 2.5M | -226.64M | -9065.91% |
| 2027 | 118.33M | -96.21M | -81.31% |
| 2028 | 286.13M | -29.63M | -10.36% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.84 | -0.81 |
|---|---|---|
| 2024-03-20 | -0.8 | -0.78 |
| 2024-05-09 | -0.84 | -0.97 |
| Jun 2023 | 286522000 | 67.75M | 23.65% |
|---|---|---|---|
| Sep 2023 | 366969000 | 68.33M | 18.62% |
| Dec 2023 | 344434000 | 78.90M | 22.91% |
| Mar 2024 | 314175000 | 75.26M | 23.96% |
| Jun 2023 | -22.41M | -89.94M | 10.19M |
|---|---|---|---|
| Sep 2023 | -26.80M | -31.17M | 108.10M |
| Dec 2023 | -21.60M | 29.46M | 313K |
| Mar 2024 | -33.00M | -57.66M | 15.06M |
HilleVax alternative data
| Aug 2023 | 62 |
|---|---|
| Sep 2023 | 62 |
| Oct 2023 | 62 |
| Nov 2023 | 62 |
| Dec 2023 | 62 |
| Jan 2024 | 62 |
| Feb 2024 | 62 |
| Mar 2024 | 90 |
| Apr 2024 | 90 |
| May 2024 | 90 |
| Jun 2024 | 90 |
| Jul 2024 | 90 |
HilleVax other data
21.22%
-49.49%
of HLVX is owned by hedge funds
32
-24
5.76M
-20.63M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 15000 |
| Dec 2023 | 0 | 30000 |
| Feb 2024 | 0 | 51972 |
| Mar 2024 | 1250 | 36000 |
| Apr 2024 | 8850 | 18000 |
| May 2024 | 0 | 24898 |
-
What's the price of HilleVax stock today?
One share of HilleVax stock can currently be purchased for approximately $2.06.
-
When is HilleVax's next earnings date?
Unfortunately, HilleVax's (HLVX) next earnings date is currently unknown.
-
Does HilleVax pay dividends?
No, HilleVax does not pay dividends.
-
How much money does HilleVax make?
HilleVax has a market capitalization of 91.39M. HilleVax made a loss 123.57M US dollars in net income (profit) last year or -$0.97 on an earnings per share basis.
-
What is HilleVax's stock symbol?
HilleVax, Inc. is traded on the NASDAQ under the ticker symbol "HLVX".
-
What is HilleVax's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of HilleVax?
Shares of HilleVax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does HilleVax have?
As Jul 2024, HilleVax employs 90 workers.
-
When HilleVax went public?
HilleVax, Inc. is publicly traded company for more then 3 years since IPO on 29 Apr 2022.
-
What is HilleVax's official website?
The official website for HilleVax is hillevax.com.
-
Where are HilleVax's headquarters?
HilleVax is headquartered at 75 State Street, Boston, MA.
-
How can i contact HilleVax?
HilleVax's mailing address is 75 State Street, Boston, MA and company can be reached via phone at +61 72135054.
HilleVax company profile:
HilleVax, Inc.
hillevax.comExchange:
NASDAQ
Full time employees:
90
Industry:
Biotechnology
Sector:
Healthcare
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
75 State Street
Boston, MA 02109
Boston, MA 02109
CIK: 0001888012
ISIN: US43157M1027
CUSIP: 43157M102
